We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

103 hedge funds and large institutions have $1.21B invested in Spyre Therapeutics in 2024 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

817% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 6

102% more capital invested

Capital invested by funds: $601M → $1.21B (+$612M)

91% more funds holding

Funds holding: 54 → 103 (+49)

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

33% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 15

602.06% less ownership

Funds ownership: 691.63% → 89.57% (-602%)

Holders
103
Holders Change
+49
Holders Change %
+90.74%
% of All Funds
1.48%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.07%
New
55
Increased
20
Reduced
15
Closed
6
Calls
$76K
Puts
–
Net Calls
+$76K
Net Calls Change
+$32K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$81.1M
2
YF
Yu Fan
+$21.4M
3
BlackRock
BlackRock
New York
+$15.6M
4
DGM
Darwin Global Management
Jersey
+$13.7M
5
FCM
Farallon Capital Management
California
+$13.5M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$21.4M
2
CAM
Cormorant Asset Management
Massachusetts
-$19.9M
3
EC
EcoR1 Capital
California
-$19.1M
4
BI
BVF Inc
California
-$14.8M
5
GEM
Global Endowment Management
North Carolina
-$14.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
26
Boxer Capital
California
$9.48M – – –
LGM
27
Logos Global Management
California
$9.48M +$2.9M +100,000 +67%
Goldman Sachs
28
Goldman Sachs
New York
$9.1M +$6.95M +239,915 New
Voloridge Investment Management
29
Voloridge Investment Management
Florida
$7.13M +$5.45M +188,053 New
SCM
30
Suvretta Capital Management
New York
$6.16M – – –
Marshall Wace
31
Marshall Wace
United Kingdom
$6.14M +$4.1M +141,669 +700%
HS
32
HighVista Strategies
Massachusetts
$5.86M -$12.3M -423,235 -73%
Invesco
33
Invesco
Georgia
$5.79M +$4.42M +152,578 New
State Street
34
State Street
Massachusetts
$5.1M +$3.89M +134,426 New
GPP
35
Great Point Partners
Connecticut
$4.74M – – –
Walleye Capital
36
Walleye Capital
New York
$4.23M +$3.23M +111,478 New
CS
37
Candriam SCA
Luxembourg
$3.98M +$3.04M +105,000 New
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$3.85M +$2.94M +101,503 New
WP
39
Woodline Partners
California
$3.81M +$2.91M +100,527 New
GTC
40
Ghost Tree Capital
New York
$3.79M +$2.9M +100,000 New
IHAM
41
Integral Health Asset Management
New York
$3.79M +$2.9M +100,000 New
NIP
42
Nicholas Investment Partners
California
$3.41M +$2.61M +89,962 New
HF
43
HRT Financial
New York
$3M +$2.29M +78,996 New
T. Rowe Price Associates
44
T. Rowe Price Associates
Maryland
$2.98M +$2.28M +78,529 New
Northern Trust
45
Northern Trust
Illinois
$2.52M +$1.92M +66,340 New
Assenagon Asset Management
46
Assenagon Asset Management
Luxembourg
$2.44M +$1.87M +64,400 New
SC
47
Stempoint Capital
New York
$2.36M -$9.17M -316,513 -84%
TD Asset Management
48
TD Asset Management
Ontario, Canada
$2.31M +$1.77M +60,968 New
Qube Research & Technologies (QRT)
49
Qube Research & Technologies (QRT)
United Kingdom
$2.19M +$1.67M +57,678 New
Morgan Stanley
50
Morgan Stanley
New York
$1.94M +$1.48M +51,108 +63,885%
1
2
3 4 5

SYRE Hedge Fund Activity: Q1 2024 in Review

103 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2024, worth a combined $1.21B — up 102% from $601M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new SYRE positions and 6 closed out — a net gain of 49 holders — while 20 added to existing stakes and 15 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $81.1M. The largest seller was Deep Track Capital, cutting an estimated $21.4M.

  • 103 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2024, up from 54 in Q4 2023.
  • Funds reported $1.21B of Spyre Therapeutics stock for Q1 2024, up 102% quarter-over-quarter.
  • 55 funds opened new Spyre Therapeutics positions in Q1 2024 and 6 closed out, a net change of +49 holders.
  • The largest Spyre Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $81.1M added.
  • The largest Spyre Therapeutics seller in Q1 2024 was Deep Track Capital, an estimated $21.4M sold.

Based on aggregated 13F filings for Q1 2024.